Cardiovascular disease in COPD: A call for action

The Lancet Respiratory Medicine

Volumn 2, Issue 10, 2014, Pages 783-785

  Bhatt, Surya P ^a   Wells, J Michael ^a,b   Dransfield, Mark T ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE;

AGING; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART PROTECTION; HUMAN; INFLAMMATION; MORBIDITY; NOTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PUBLIC HEALTH; RESPIRATORY FAILURE; SITTING; SMOKING; SYMPATHETIC TONE; COMPLICATION; MORTALITY; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84908021284     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70197-3     Document Type: Note

References (15)

1. Mannino DM, Buist AS Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370:765-773.
2. Bhatt SP, Dransfield MT Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013, 162:237-251.
3. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137:1091-1097.
4. Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1091-1099.
5. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
6. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010, 33:1395-1402.
7. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014, 63:713-735.
8. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
9. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care 2010, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, London.
10. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155:179-191.
11. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013, 144:758-765.
12. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
13. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010, 65:719-725. for the TORCH Investigators.
14. Ekström MP, Hermansson AB, Ström KE Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:715-720.
15. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010, 170:880-887.